ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...
(HealthDay News) — For patients with end-stage cancer, chemotherapy use does not improve quality of life near death (QOD), even for those with good performance status, according to a study published ...
Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis. Mark Socinski, MD: Martin, we have seen ...
The frontline combination of zanidatamab-hrii (Ziihera) and chemotherapy with or without tislelizumab (Tevimbra) was ...
CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback